|
Guide |
|
Abstract 【Abstract】Objective: To investigate the diagnosis and treatment of neonatal Acinetobocter johnsonii (AJ) infection by summarizing the clinical characteristics and treatment outcome of neonatal sepsis caused by AJ. Method: The clinical details of 2 cases of neonatal AJ sepsis were retrospectively analyzed, and the relevant literature was consulted for analysis. Result: Two cases with gestational age of 26+5 weeks and 34 weeks, birth weight of 1050 g and 1800 g, developed sepsis on postnatal days 21 and 23, separately, which were confirmed to have AJ infection by blood culture and were discharged uneventfully after 40 and 36 days of hospitalization after treatment. Conclusion: AJ is a rare human infectious pathogen. The diagnosis depends on blood culture. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry can help AJ identification. The selection of antibacterial drugs should be based on the results of drug susceptibility testing and MIC values, as well as the physiological state of the children themselves.
|
Received: 21 June 2021
Published: 01 January 2022
|
|
Corresponding Authors:
Zongtai Feng
|
|
|
|
|
参考文献
|
[1] |
Nguyen M, Joshi SG. Carbapenem resistance in Acinetobacter baumannii, and their importance in hospital-acquired infections: a scientific review[J]. J Appl Microbiol. 2021; 10.1111.
|
[2] |
田国忠,崔步云.约翰逊不动杆菌研究进展[J].中华流行病学杂志,2011(03):316-319.
|
[3] |
Castillo-Ramírez S, Mateo-Estrada V, Gonzalez-Rocha G, Opazo-Capurro A. Phylogeographical Analyses and Antibiotic Resistance Genes of Acinetobacter johnsonii Highlight Its Clinical Relevance[J]. mSphere. 2020;5(4):e00581-20.
|
[4] |
Bouvet P J M, Grimont P A D. Taxonomy of the genus Acinetobacter with the recognition of Acinetobacter baumannii sp. nov., Acinetobacter haemolyticus sp. nov., Acinetobacter johnsonii sp. nov., and Acinetobacter junii sp. nov. and emended descriptions of Acinetobacter calcoaceticus and Acinetobacter lwoffii[J]. International Journal of Systematic and Evolutionary Microbiology, 1986, 36(2): 228-240.
|
[5] |
Bouvet PJ, Grimont PA. Identification and biotyping of clinical isolates of Acinetobacter[J]. Ann Inst Pasteur Microbiol. 1987;138(5):569-578.
|
[6] |
翟盼盼,吴宇骞,陆坚.不动杆菌属分类的研究进展[J].新发传染病电子杂志,2020,5(01):51-55.
|
[7] |
Cleland EJ, Bassiouni A, Vreugde S, Wormald PJ. The bacterial microbiome in chronic rhinosinusitis: richness, diversity, postoperative changes, and patient outcomes[J]. Am J Rhinol Allergy, 2016, 30(1):37-43.
|
[8] |
Turton JF, Shah J, Ozongwu C, Pike R. Incidence of Acinetobacter species other than A. baumannii among clinical isolates of Acinetobacter: evidence for emerging species[J]. Journal of clinical microbiology,2010,48(4):1445-1449.
|
[9] |
Seifert H, Strate A, Schulze A, Pulverer G. Vascular Catheter-Related Bloodstream Infection Due to Acinetobacter johnsonii (Formerly Acinetobacter calcoaceticus var. lwoffii): Report of 13 Cases[J]. Clinical Infectious Diseases, 1993, 17(4): 632-636.
|
[10] |
Zong G, Zhong C, Fu J, et al. The carbapenem resistance gene bla OXA-23 is disseminated by a conjugative plasmid containing the novel transposon Tn 6681 in Acinetobacter johnsonii M19[J]. Antimicrobial Resistance & Infection Control, 2020, 9(1): 1-11.
|
[11] |
陈亮,李真.不动杆菌属对碳青霉烯类抗菌药物的耐药机制与治疗[J].中华医院感染学杂志,2013,23(12):3035-3037.
|
[12] |
Monta?a S, Schramm S T J, Traglia G M, et al. The genetic analysis of an Acinetobacter johnsonii clinical strain evidenced the presence of horizontal genetic transfer[J]. PLoS One, 2016, 11(8): e0161528.
|
[13] |
Feng Y, Yang P, Wang X, et al. Characterization of Acinetobacter johnsonii isolate XBB1 carrying nine plasmids and encoding NDM-1, OXA-58 and PER-1 by genome sequencing[J]. Journal of Antimicrobial Chemotherapy, 2016, 71(1): 71-75.
|
[14] |
Rodríguez C H, Nastro M, Dabos L, et al. First isolation of Acinetobacter johnsonii co-producing PER-2 and OXA-58 β-lactamases[J]. Diagnostic microbiology and infectious disease, 2014, 80(4): 341-342.
|
[15] |
Tsuchida S, Umemura H, Nakayama T. Current Status of Matrix-Assisted Laser Desorption/Ionization-Time-of-Flight Mass Spectrometry (MALDI-TOF MS) in Clinical Diagnostic Microbiology. Molecules. 2020;25(20):4775。
|
|
|